Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG100801 in Patients With Choroidal Neovascularization Due to AMD
NCT00509548Phase 2Terminated
- Sponsor
- TargeGen, Inc.
- Start
- Jul 2007
- Primary completion
- Mar 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TG100801 in exudative macular degeneration, sponsored by TargeGen, Inc.. Started Jul 2007; status: terminated.
02
Drugs
TG100801
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00509548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509548.